BioInorganic Chemistry Investigation on encapsulated Cysteine derivative

Recently Cysteine has been introduced as an agent of suppression of μ- and m-calpain activities and followed by that neuroprotective compound. The main objective of this research was to investigate the neuroprotective potential of the encapsulated Cysteine derivatives into polymeric nanocarriers (NCs). The copolymer-based synthesized Cysteine-loaded nanocarriers were prepared from coprecipitation method at constant temperature followed by evaporation of an organic solvent. To the best of our knowledge, it is the first time to investigate the biocompatibility and neuroprotective potential of Cysteine derivatives loaded into PEG-b-PCL (poly (ethylene glycol)-block-poly (ε−caprolactone) methyl ether). The average size of the polymeric/empty NCs was 89 nm and for PEG-b-PCL/Synthesized derivative of Cysteine was 126 nm. The Drug Loading efficiency was 81%. The concentration of Polymeric NCs was 2.1 x 10 10 particles/ml and the zeta potential of polymeric/empty and polymeric/ Synthesized derivative of Cysteine NCs -5 mV and -11 mV respectively. Biocompatibility and Neuroprotective potential of NCs were evaluated in the SH-SY5Y human neuroblastoma cell line using cell viability and toxicity assays. The concentration of polymeric NCs below 1 x 10 10 particles/ml can be considered as a safe concentration for the cell line. Also the Synthesized derivative of Cysteine encapsulated into polymeric NCs have more neuroprotective effect compared to free Cysteine at lower concentration, and therefore, have a significant neuroprotective potential against Z-VAD-fmk and St-evoked SH-SY5Y cell damage.[1-3]